Treatment of IBS-D with 5-HT3 receptor antagonists vs spasmolytic agents: similar therapeutical effects from heterogeneous pharmacological targets

Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome

(2011) P. Clavé et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine

(2011) K. J. Lee et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Effect of otilonium bromide on contractile patterns in the human sigmoid colon

(2010) D. Gallego et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents

(2010) Anita Sainsbury et al.   Therapeutic Advances in Gastroenterology

Efficacy of 5-HT3 Antagonists and 5-HT4 Agonists in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis

(2009) Alexander C Ford et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Contributions of Pain Sensitivity and Colonic Motility to IBS Symptom Severity and Predominant Bowel Habits

(2008) Motoyori Kanazawa et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Effects of excitatory and inhibitory neurotransmission on motor patterns of human sigmoid colon in vitro

(2008) M Aulí et al.   BRITISH JOURNAL OF PHARMACOLOGY